1. Expanding The Indications For CSII and CGMS Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia

2. U.S. Diabetes Prevalence —Diabetes kills 1 American every 3 minutes —New case diagnosed every 40 seconds —More deaths than AIDS and breast cancer combined —Average life expectancy: 15 years less than non- diabetes population —Afflicts over 120 million people worldwide —300 million afflicted by 2025 18 Million

3. Undiagnosed diabetes ~5.2 million Prevalence of Glycemic Abnormalities in the United States Additional 25 -35 million with IGT Diagnosed type 2 diabetes ~12 million Diagnosed type 1 diabetes ~1.0 million Centers for Disease Control. Available at: http://www.cdc.gov/diabetes/pubs/estimates.htm; Harris MI. In: National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md: NIDDK; 1995:15-36; U.S. Census Bureau Statistical Abstract of the U.S.; 2001 US Population: 275 Million in 2000 3

4. World View 4th leading cause of death by disease India 33 million people with diabetes China 23 million people with diabetes Population of diabetes will double to triple by 2025 One out of every three Americans born today will develop diabetes Time magazine December 2003; CDC

5. Relative Risk of Progression of Diabetic Complications DCCT Research Group, N Engl J Med 1993, 329:977-986. RELATIVE RISK Mean HbA 1c

6. Gain of 15.3 years of complication free living compared to conventional therapy Gain of 5.1 years of life compared to conventional therapy Lifetime Benefits of Intensive Therapy (DCCT) DCCT Study Group, JAMA 1996, 276:1409-1415.

7. DCCT 10% reduction in A1C 43% reduced risk of retinopathy progression 18% increased risk of severe hypoglycemia with coma and/or seizure DCCT Research Group, N Engl J Med 1993, 329:977-986.

8. *Percent risk reduction per 0.9% decrease in HbA 1C ; UKPDS. Lancet. 1998;352:837-853. Lowering A1C Reduces Risk of Complications Reduction in risk (%)* p=0.029 p=0.0099 p=0.052 p=0.015 p=0.000054 0 -10 -20 -30 -40 -50 -12 -25 -16 -34 -21 Any diabetes- related endpoint Microvascular endpoint MI Retinopathy Albuminuria at 12 years United Kingdom Prospective Diabetes Study (UKPDS)

9. Lessons from the DCCT and UKPDS: Sustained Intensification of Therapy is Difficult DCCT EDIC (Type 1) UKPDS (Type 2), Insulin Group DCCT/EDIC Research Group. New Engl J Med 2000; 342:381-389 Steffes M et al. Diabetes 2001; 50 (suppl 2):A63 UK Prospective Diabetes Study Group (UKPDS) 33 Lancet 1998; 352:837-853 4 6 8 10 9.0 8.1 7.3 7.9 06.5+ 4+ 6 yrs DCCT EDIC 0 6 7 8 0246810 yrs A1C (%) Normal Baseline A1C (%)

10. Primary Objectives of Effective Management A1C % SBP mm Hg LDL mg/dL 455055 6065 70 75 808590 9 Diagnosis 8 7 130 100 145 140 Patient Age Reduction of both micro- and macro- vascular event rates …by 75%! lGæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.

11. Goals of Targeted Insulin Therapy (Intensive/Physiologic/Flexible) Maintain near-normal glycemia Avoid short-term crisis Minimize long-term complications Improve the quality of life 01224 Hours

12. Specific Goals in Management of Diabetes Fasting or premeal BG 70 to 140 mg/dL Post-meal < 140 mg/dL A1C < 6.5% Blood Pressure < 130/80 LDL 45 mg/dL Triglycerides < 150 mg/dL

13. Insulin The most powerful agent we have to control glucose

14. Patient J.L., December 15, 1922 February 15, 1923 The Miracle of Insulin

15. Progression of Type 1 Diabetes Adapted from: Atkinson. Lancet. 2002;358:221-229. Age (y) Precipitating Event Beta-cell mass Genetic predisposition Normal insulin release Glucose normal Overt diabetes No C-peptide present Progressive loss of insulin release C-peptide present Antibody

16. Options in Insulin Therapy for Type 1 Diabetes Current —Multiple injections —Insulin pump (CSII) Future —Implant (artificial pancreas) —Transplant (pancreas; islet cells)

17. Type 2 Diabetes … A Progressive Disease Over time, most patients will need insulin to control glucose

18. Multiple factors may drive progressive decline of  -cell function  -cell (genetic background) Hyperglycaemia (glucose toxicity) Protein glycation Amyloid deposition Insulin resistance “lipotoxicity” elevated FFA,TG

19. 4:00 25 50 75 8:0012:0016:0020:0024:004:00 BreakfastLunchDinner Plasma insulin (U/ml) Plasma insulin ( µ U/ml) Time 8:00 Physiological Serum Insulin Secretion Profile

20. 0600 Time of day 20 40 60 80 100 BLD Multiple Daily Injections Human Insulins B=breakfast; L=lunch; D=dinner 0600 0800 1800 12002400 0600 Regular NPH Regular Normal pattern  U/mL Regular

21. Barriers to Intensive Insulin Therapy Severe Hypoglycemia DCCT. Diabetes 1997;46:271-86 UKPDS. Lancet 1998;352:837-853 Type 1 Diabetes in the DCCT Conventional insulin 35% of pts19 events/100pt-yr A1c ~9%, 6 yr Intensive insulin 65% of pts61 events/100 pt-yr A1c 7.2%, 6 yr Type 2 Diabetes in the UKPDS Intensive policy insulin 2.3%/yr A1c 7.0%, 10 yr

22. 4:0016:0020:0024:004:00 BreakfastLunchDinner 8:00 12:008:00 Time Basal infusion Bolus Plasma insulin Variable Basal Rate: CSII Program

23. CSII Reduces Hypoglycemia Chantelau, E et al., Diabetologia 1989, 32:421-6. Bode, BW et al., Diabetes Care 1996, 19:324-7. Boland, EA et al., Diabetes Care 1999, 22:1779-84. Maniatis AK, et al., Pediatrics 2001, 107:351-6. n=55 Mean age 42 n=107 Mean age 36 n=116 Mean age 29 n=25 Mean age 14 n=56 Mean age 17 Events per hundred patient years Bode Rudolph Chanteleau Boland Maniatis

24. CSII Reduces A1C Chantelau, E et al., Diabetologia 1989, 32:421-6. Bode, BW et al., Diabetes Care 1996, 19:324-7. Boland, EA et al., Diabetes Care 1999, 22:1779-84. Bell, DSH et al., Endocrine Practice 2000, 6:357-60. Maniatis AK, et al., Pediatrics 2001, 107:351-6. n= 58 n=107 n=116 n=50 n=25 n=56 Adolescents Adults Mean Dur.=36 Mean Dur.=54Mean Dur.=42Mean Dur.=12 Bell Rudolph Chanteleau Bode Boland Maniatis

25. DCCT: Diabetes Care 1995; 18:361-376. Pump 42% MDI 56% Unknown 2% Insulin Delivery Therapy at end of DCCT

26. 4:0016:0020:0024:004:00 BreakfastLunchDinner 8:00 12:008:00 Time Glargine Plasma insulin Basal/Bolus Treatment Program with Rapid-acting and Long-acting Analogs LisproLisproLispro AspartAspartAspart or

27. Intrasubject Variability (GIR) With Lantus ® (insulin glargine) Scholtz et al.Diabetologia.1999;42(suppl 1):A235. Glucose infusion rate (mg/kg/min) Subject 14 Subject 16 Subject 19 Subject 22 Subject 27 Subject 28 Subject 34 Subject 36 4 4 9 9 14 19 24 4 4 9 9 14 19 24 4 4 9 9 14 19 24 4 4 9 9 14 19 24 11.0 8.8 6.6 4.4 2.2 0.0 11.0 8.8 6.6 4.4 2.2 0.0 11.0 8.8 6.6 4.4 2.2 0.0 Visit 2 Visit 3 Time (h) Subject 2 Subject 3 Subject 7 Subject 9

28. Insulin aspart (CSII) vs insulin aspart / glargine (MDI) Run-in (1 week)Period 1 (5 weeks)Period 2 (5 weeks) IAsp CSII IAsp + Gar MDI CSII vs MDI with Glargine in Adults Bode, et al. Diabetes 52,(Suppl 1), 2003 Abstract 438. 100 patients with type 1 on CSII at entry A1C <9% Efficacy: A1C, fructosamine, 8-point BG profile, glucose exposure (CGMS) Safety: frequency of hypoglycemia, AEs

29. Pumps vs MDI: Characteristics of Enrolled Population Data of file, Novo Nordisk. ANA-2155 Treatment Sequence a CSII to MDIMDI to CSIIAll Subjects Subjects Treated50 100 Age (years) 41.7  11.144.2  11.043.0  11.1 BMI (kg/m 2 ) 27.1  4.126.7  4.026.9  4.0 A1C at screening (%) 7.5  0.87.4  0.87.5  0.8 Duration of diabetes (years) 19.7  11.323.9  12.321.8  11.9 Daily insulin dose 42.3  17.9 (n = 45) 41.6  16.1 (n = 50) 41.9  16.9 (n = 95) Basal 21.1  8.122.6  10.721.9  9.2 Bolus 22.7  13.819.3  8.720.9  11.4

30. CSII vs MDI: Better BG Control Bode, et al. Diabetes 52,(Suppl 1), 2003 Abstract 438. Mean ± 2 SEM 200 160 140 120 100 180 Self- monitored BG (mg/dL) BBAB BL ALBDADMidnight 3 AM CSII (n=93) MDI (n=91)

31. n=63 in each treatment 0 500 1000 1500 2000 2500 3000 CSII MDI P=0.0027 *Measurement of AUC (glu) ≥80 mg/dL during the 48-hour continuous glucose monitoring period. AUC glu (mgh/dL) Bode, et al. Diabetes 52,(Suppl 1), 2003 Abstract 438. CSII vs MDI: Less Glucose Exposure

32. CSII vs MDI: Rate of Hypoglycemia Episodes/subject/5 weeks 12 10 8 6 4 2 0 TotalDaytimeNocturnal P=0.0039 P<0.0001 P=0.0006 CSII MDI Bode, et al. Diabetes 52,(Suppl 1), 2003 Abstract 438.

33. CSII vs MDI with Glargine in Children – Preliminary Data Boland et al., Diabetes 2003, 52:S1, A45, 192-OR Subjects at baseline Age: 8-19 yr (mean 12.7 ± 2.7) Type 1 DM > 1 yr duration Standard insulin therapy (2-3 injections/day) CSII (aspart) n=12 MDI (aspart/glargine) n=14 16 Week treatment period Injection therapy Randomized, Parallel-group, 16 week study

34. 6 6.5 7 7.5 8 8.5 9 Baseline4 weeks8 weeks12 weeks16 weeks Glargine (n=16) CSII (n=14) CSII vs. MDI with Glargine in Children (Preliminary Data) Boland, E. Diabetes 52,(Suppl 1), 2003 Abstract 192. A1c

35. CSII vs MDI in Children – Preliminary Data Safety and Preference Safety Severe hypoglycemic episodes MDI: 4 CSII: 2 No cases of DKA Preference (at 16 weeks) All 12 CSII subjects remained on CSII 12 of 14 MDI subjects switched to CSII Boland et al., Diabetes 2003, 52:S1, A45, 192-OR

36. CSII Reduced HbA1c in Type 2 Patients 7.0 7.2 7.4 7.6 7.8 8.0 8.2 8.4 CSIIMDI Baseline End of study (24 weeks) Raskin et al. Diabetes. 2001;50(suppl 2):A128. A1C (%) N=127

37. Change in scores (raw units) from baseline to endpoint -505101520253035 Convenience Less burden Less hassle Advocacy Preference General satisfaction Flexibility Less life interference Less pain Fewer social limitations MDICSII Patient Satisfaction in Type 2 DM Testa et al. Diabetes. 2001;50(suppl 2):1781

38. Metabolic Advantages with CSII Improved glycemic control Better pharmacokinetic delivery of insulin —Less hypoglycemia —Less insulin required Improved quality of life

39. N=165. Average duration=3.6 years. Average discontinuation <1%/y. Continued 97% Discontinued 3% Current Continuation Rate: Continuous Subcutaneous Insulin Infusion (CSII) Bode BW, et al. Diabetes. 1998;47(suppl 1):392.

40. US Pump Usage: Total Patients Using Insulin Pumps Industry estimates

41. Photograph reproduced with permission of manufacturer.

42. Pump Infusion Sets

43. Evolution of Pump Indications Severe Hypoglycemia Hypoglycemia unawareness Dawn phenomenon Pregnancy Pre-conception Shift workers Gastroparesis Athletes Pediatrics 1980s 2000 1990s

44. Current Pump Therapy Indications Diagnosed with diabetes (even new-onset type 1 diabetes) Need to normalize blood glucose —A1C > 6.5% —Glycemic excursions —Hypoglycemia Need for flexible insulin program

45. Pump Therapy-Getting Started Basal rate Continuous flow of insulin Takes the place of NPH or glargine insulin Meal boluses Insulin needed premeal —Premeal BG —Carbohydrates in meal —Activity level Correction bolus for high BG Meal bolus 1 2 3 4 5 6 12 AM 12 PM 12 AM Time of day Basal rate Units

46. Monitoring —A1C = 8.3 - (0.21 x BG per day) Recording 7.4 vs 7.8 Diet practiced —CHO: 7.2 —Fixed: 7.5 —WAG: 8.0 Insulin type (Aspart) CSII Factors Affecting A1C Bode et al. Diabetes 1999;48 Suppl 1:264 Bode et al. Diabetes Care 2002;25 439

47. Initial Adult Dosage: Calculations Starting doses Based on pre-pump total daily dose (TDD)  reduce TDD by 25% to 30% for pump TDD Calculated based on weight  0.24 x weight in lb (0.53 x weight in kg) Bode BW, et al. Diabetes. 1999;48(suppl 1):84. Bell D, Ovalle F. Endocr Pract. 2000;6:357-360. Crawford LM. Endocr Pract. 2000;6:239-243.

48. Hypoglycemic unawareness —Preprandial:100 - 160 mg/dl Pregnant —Preprandial:60 - 90 mg/dl —1 hr postprandial:<120 mg/dl Individually set for each patient Target BG Ranges for CSII Fanelli CG et al., Diabetologia 1994, 37:1265-76. Jovanovich L, AMJObGynec 1991, 164:103-11.

49. Initial Adult Dosage: Calculations Basal rate 45% to 50% of pump TDD Divide total basal by 24 hours to decide on hourly basal Start with only 1 basal rate See how it goes before adding basals

50. Basal Dose Adjustment Overnight Rule of 30: Check BG Bedtime 12 AM 3 AM 6AM Adjust overnight basal if readings vary > 30 mg/dl

51. Adults often need an increase in basal rate in the “Dawn” hours (4 am to 9 am) Children often need an increase in basal rate earlier starting at 10 pm to 2 am Basal Dose Adjustment Overnight

52. 4:0016:0020:0024:004:00 BreakfastLunchDinner 8:00 12:008:00 Time Basal infusion Bolus Plasma insulin Variable Basal Rate: CSII Program

53. Basal Dose Adjustment Daytime Rule of 30: Check BG Before usual meal time Skip meal Every 2 hrs (for 6 hrs) Adjust daytime basal if readings vary > 30 mg/dl

54. Bolus Dose Calculations Meal (food) Bolus Method 1 Test BG before meal Give pre-determined insulin dose for pre-determined CHO content Test BG after meal Goal < 60 mg/dl rise post meal or < 160 mg/dl

55. Individually determined CIR = (2.8 x wgt in lbs) / TDD Anywhere from 5 to 25 g CHO is covered by 1 unit of insulin Estimating the Carbohydrate to Insulin Ratio (CIR) Davidson et al: Diabetes Tech & Therap. April 2003

56. Estimating the Carbohydrate to Insulin Ratio (CIR) Alternative Method: 500 Rule: 500 divided by TDD Example: 500 / 50 = 10 Insulin to carb ratio = 1u for 10g

57. What Type of Bolus to Use? 9 DM 1 patients on CSII ate pizza, tiramisu, and coke on four consecutive Saturdays Single bolus Double bolus at -10 and 90 min Square wave bolus over 2 hours Dual wave bolus (70% at meal, 30% as 2-h square) Chase HP et al: Diabetic Medicine 2002;19:317-321

58. -40 -20 0 20 40 60 80 100 BG Change from Baseline in mg/dl 1 bolus 2 bolus Square Dual Comparison of Pump Boluses with High Carbohydrate & High Fat Meal 0.51.0 1.5 2.0 4.0 5.0 Hours from Baseline Chase HP et al: Diabetic Medicine 2002;19:317-321

59. Correction Bolus Must determine how much glucose is lowered by 1 U of rapid-acting insulin This number is known as the correction factor (CF) Use the 1700 rule to estimate the CF CF=1700 divided by TDD example: if TDD=36 U, then CF=1700/36=  50, meaning 1 U will lower the BG  50 mg/dL

60. Correction Bolus Formula Example: —Current BG:220 mg/dL —Ideal BG: 100 mg/dL —Glucose CF: 50 mg/dL Current BG - Ideal BG Glucose Correction Factor 220 - 100 50 = 2.4 U

61. If A1C is Not to Goal SMBG frequency and recording Diet practiced —Do they know what they are eating? —Do they bolus for all food and snacks? Infusion site areas —Are they in areas of lipohypertrophy? Other factors: —Fear of low BG —Overtreatment of low BG Must look at:

62. If A1C Is Not at Goal and No Reason Identified Place on a continuous glucose monitoring system CGMS by Medtronic MiniMed or GlucoWatch by Cygnus to determine the cause

63. GlucoWatch ® Biographer

64. CGMS

65. CGMS Sensor

66. Monitor and Com-Station

67. Case Study # 1 GL, male, age 39 Type 1 X 8 years A1C= 7%; recent increase from 6% CSII basal rates: 12 am 1.0 u/h; 4:30 am 1.6 u/h; 11:30 am 1.0 u/h Insulin: carbohydrate ratio =1u : 10 grams Correction Factor: BG - 100 divided by 40 CGMS done to assist with improving overall glycemic control

68. Modal Day View

69. Cheese / Crackers 20 g; 3units 30 gm CHO; Heavy Exercise 80 CHO; 7u 2u; 57 g CHO Milk choc 15g; 8u Juice box; no insulin Ice Cream; 3 u 6u

70. Bolus: Source of Errors “Inability” to count carbs correctly — Lack of knowledge, skill — Lack of time — Too much work Incorrect use of SMBG number Incorrect math in calculation “WAG” estimations

71. Most common bolusing errors Under-estimation of carbohydrates consumed (CHO bolus) Over-correction of post-prandial elevations (CF bolus) — Remaining unused, active insulin — Stacking of boluses

72. Dosing Tools: The FUTURE

73. Monitor sends BG value to pump via radio waves : No transcribing error Enter carbohydrate intake into pump “Bolus Wizard” calculates suggested dose Paradigm Link ™ Paradigm 512 ™ ) ) ) ) ) ) ) ) ) ) ) ) ) Bolus Wizard Calculator : meter-entered

74. Paradigm ® 512 Pump Customizable Basal and Bolus Options —Dual Wave —Basal Patterns BG Testing Reminders High or Low Blood Glucose Alerts Vibrate or Beep Mode Wireless Remote (optional) Safety Block

75. The Bolus Wizard™ Calculator Can be customized with up to 8 different setting per day for: —Blood glucose targets —Carbohydrate ratios —Insulin-sensitivity factors Simplifies Diabetes Management —Reduces math errors —Decreases the number of correction boluses required * —Lowers the entry error rate when using the Paradigm Link TM Blood Glucose Monitor, powered by BD Logic TM Technology

76. Bolus Wizard TM Calculator Uses an Active Insulin Formula Based on insulin pharmacodynamic data Helps prevent insulin stacking

77. Insulin Activity Over Time 0 100 200 300 400 500 600 700 012345678 Rapid Acting Regular Insulin Activity (GIR) Time (hrs) Insulin Pharmacodynamic Data Adapted from Henry R: Diabetes Care 1999

78. 0 20 40 60 80 100 0 1 2345 678 Rapid Acting Regular Time (hrs) Percent Remaining Adjusting for Active Insulin: How smart pumps do it

79. Wizard: On Carb Units: grams Carb Ratios: 10 BG Units: mg/dl Sensitivity: 50 BG Target: 100 Bolus Wizard Set Up Screen

80. Breakfast - Step 1. Check BG Use the Paradigm Link™, powered by BD Logic™ Technology or their currrent meter

81. Robin accepts the transferred blood glucose value —Requires confirmation —Can change glucose value if necessary Breakfast - Step 2. Accept BG Enters CHO grams —53 grams of carbohydrate

82. The Paradigm ® presents the dose —5.3 U for 53 grams carb (CIR = 10) —No correction dose —Shows total 5.3 U Accept suggested dose Pump delivers dose Breakfast - Step 3. Accept Dose

83. Robin has a late lunch at 2:10 PM — Blood glucose 160 — Accepts the transferred BG value Late Lunch - Step 1,2 Enters CHO grams — 50 grams of carbohydrate 50

84. The Paradigm ® presents the dose —5.0 U for 50 grams carb (CIR = 10) —Correction dose = 1.2 U (160-100) / 50 = 60/50 = 1.2 —Shows total 6.2 U Accept suggested dose Pump delivers dose Late Lunch - Step 3. Accept Dose

85. Enters CHO grams —50 grams of carbohydrate 50 Robin plans to have appetizers at 5:30 PM — This is only 3.5 hours after lunch. — There is still an active insulin depot — Blood glucose is 157 — Accepts the transferred BG value Early Supper - Step 1,2

86. The Paradigm ® presents the dose — 5.0 U for 50 grams carb (CIR = 10) — Correction dose = 1.1 U (157 -100)/50 — Remaining active insulin = 2.6 U — Remaining active insulin > correction dose — No correction dose is recommended — Total shows 5.0 U Early Supper - Step 3. Accept Dose Accept dose Pump delivers dose

87. Paradigm ® Pathway to Future Diabetes Management As technology advances, so does the Paradigm pump New tools and applications will be available —Wireless communication —More memory and brain power

88. Do Smart Pumps Enable Others To Go To CSII? YES All patients with diabetes not at goal are candidates for Insulin Pump Therapy - Type 1 any age - Type 2 - Diabetes in Pregnancy

89. Summary Insulin remains the most powerful agent we have to control diabetes When used appropriately in a basal/bolus format, near-normal glycemia can be achieved Newer insulins and insulin delivery devices along with glucose sensors will revolutionize our care of diabetes

90. Questions For a copy or viewing of these slides, contact WWW.adaendo.com